OTC: JWCTF - JW (Cayman) Therapeutics Co. Ltd

半年間の収益性: -36.47%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール JW (Cayman) Therapeutics Co. Ltd

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

さらに詳しく
The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cny
Сайт https://www.jwtherapeutics.com
Цена ао 0.162
1日あたりの価格変動: -0% (0.162)
週ごとの価格変動: -0% (0.162)
月ごとの料金変更: -0% (0.162)
3ヶ月間の価格変動: -0% (0.162)
半年間の価格変動: -36.47% (0.255)
年間の価格変動: -37.69% (0.26)
3年間の価格推移: -85.07% (1.085)
年初からの価格変動: -4.59% (0.1698)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 4.52 3
P/BV 0.4665 10
P/E 0 0
EV/EBITDA -0.2077 0
合計: 5.38

効率

名前 意味 学年
ROA, % -35.79 0
ROE, % -45.61 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.588 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % 3070.82 10
収益性 Ebitda, % 108.61 10
収益性 EPS, % 9.47 2
合計: 6.2
さらに詳しく

機関 音量 共有, %
DFA Emerging Markets Small Cap Series 467500 0.11
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 336309 0.08
DFA Emerging Markets Core Equity Portfolio 98500 0.02
Dimensional ETF Tr-Dimensional Emerging Markets Core Equity 2 ETF 95500 0.02
SPDR (R) Idx Shares-SPDR (R) S&P (R) China ETF 76500 0.02
Dimensional ETF Tr-Dimensional World ex U.S. Core Equity 2 ETF 69500 0.02
DFA Investment Dimensions-World Ex U.S. Core Equity Port 55500 0.01
SPDR (R) Idx Shares-SPDR (R) Emerging Markets Small Cap ETF 42350 0.01
DFA Investment Dimensions-DFA Emerging Markets Targeted Value Port 38000 0.01
Avantis Emerging Markets Equity ETF 36000 0.01



スーパーバイザー 役職 支払い 生年
Dr. Yiping Li M.D. Co-Founder & Interim Chairman 836.74k 1964 (61 年)
Cao Xiaoping Ph.D. Senior Vice President of Tech Operations N/A
Dr. Shaun Paul Cordoba Ph.D. Senior VP & Chief Scientific Officer N/A 1980 (45 年)
Mr. Raymond J. Hage Jr. Senior Vice President of Corporate Development N/A 1968 (57 年)
Mr. Mark J. Gilbert M.D. Senior Advisor & Acting Chief Medical Officer N/A
Ms. Ka Man Ng A.C.I.S., A.C.S. Company Secretary N/A 1978 (47 年)
Mr. Qiang Ma Senior VP & Chief Commercial Officer N/A 1978 (47 年)
Ms. Yun Qin Senior Vice President of Clinical Sciences & Medical Services N/A 1982 (43 年)
Dr. Su Yang Senior Vice President Of Clinical Research & PMO N/A 1979 (46 年)
Mr. Min Liu CEO & Executive Director 1973 (52 年)

住所: China, Shanghai, Building B - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.jwtherapeutics.com